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Tumor-associated macrophages play critical roles
during tumor progression by promoting angiogen-
esis, cancer cell proliferation, invasion, and metas-
tasis. Cysteine cathepsin proteases, produced by
macrophages and cancer cells, modulate these pro-
cesses, but it remains unclear how these typically
lysosomal enzymes are regulated and secreted
within the tumor microenvironment. Here, we identify
a STAT3 and STAT6 synergy that potently upregu-
lates cathepsin secretion by macrophages via
engagement of an unfolded protein response (UPR)
pathway. Whole-genome expression analyses re-
vealed that the TH2 cytokine interleukin (IL)-4 syner-
gizes with IL-6 or IL-10 to activate UPR via STAT6
and STAT3. Pharmacological inhibition of the UPR
sensor IRE1a blocks cathepsin secretion and blunts
macrophage-mediated cancer cell invasion. Simi-
larly, genetic deletion of STAT3 and STAT6 signaling
components impairs tumor development and inva-
sion in vivo. Together, these findings demonstrate
that cytokine-activated STAT3 and STAT6 cooperate
in macrophages to promote a secretory phenotype
that enhances tumor progression in a cathepsin-
dependent manner.INTRODUCTION
Tumor-associated macrophages (TAMs) play critical roles in
multiple stages of tumorigenesis and also contribute to chemo-
resistance (Quail and Joyce, 2013; Noy and Pollard, 2014; Ruffell
and Coussens, 2015). Through reciprocal interactions with
cancer cells and immune cell infiltrates, TAMs sculpt the tumor
microenvironment (TME) to regulate critical aspects of tumor
progression, including local inflammation, angiogenesis, cancer
cell invasion, and intravasation into the circulation (Qian and2914 Cell Reports 16, 2914–2927, September 13, 2016 ª 2016 The A
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a wide range of TAM-derived cytokines, growth factors, and
proteases that mediate autocrine/paracrine signaling as well
as modifications to the extracellular matrix (ECM). These
factors often enhance the malignant phenotype of cancer cells
and, thus, impart additional advantages to these cells within
the TME. Therefore, understanding how TAM-derived factors
interact and collectively regulate cancer cell behavior is essential
for elucidating TAM biology and developing novel TAM-based
therapies.
Among TAM-supplied proteases, members of the cysteine
cathepsin family have been implicated in multiple aspects of
carcinogenesis, including cancer cell proliferation, angiogen-
esis, invasion, and metastasis, in different tumor types (Olson
and Joyce, 2015). Typically, cathepsins are synthesized as
pro-form zymogens that can be activated in the acidic lysosomal
compartment and, thus, execute intracellular degradation of
proteins delivered to the lysosome (Turk et al., 2012). However,
numerous studies have shown that several cathepsin family
members also perform extra-lysosomal functions, such as anti-
gen presentation (Riese et al., 1996), inflammasome activation
(Hornung et al., 2008), and growth factor processing (Wiley
et al., 1985). Importantly, when secreted into the extracellular
space, these enzymes can degrade the ECM and basement
membranes, cleave cell-adhesion molecules, and participate in
proteolytic cascades, resulting in sequential protease activation,
which collectively promotes tumor invasion and metastasis (Ol-
son and Joyce, 2015). Therefore, elucidation of the molecular
mechanisms governing the secretion and extracellular activities
of cathepsins is critical.
Previously, we demonstrated that interleukin (IL)-4 signaling is,
at least partially, responsible for inducing high cathepsin activity
levels in TAMs, in addition to its role in controlling other facets of
macrophage biology (Gocheva et al., 2010b; Wang and Joyce,
2010). However, as TAMs typically reside in complex TMEs
composed of diverse cytokines, it remains to be determined
whether other factors operate in concert with IL-4 to mediate co-
ordinated responses. Indeed, aside from IL-4, other cytokines,
including IL-13, IL-6, and IL-10, readily activate macrophages
(Biswas and Mantovani, 2010). It has recently been reporteduthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Expression of TH2-Associated
Cytokine Signaling Molecules in Constitu-
ent Cell Types within the RT2 Tumor Micro-
environment
(A and B) Gene expression in mixed live cells
or FACS-purified macrophages (CD45+, F4/80+,
GR.1), T cells (CD45+, CD3+, GR.1), and cancer
cells (CD45, CD31) from wild-type (WT) RT2
tumors was analyzed by qRT-PCR for (A) Il4, Il6,
Il10, and Il13; and (B) Il4ra, Il6ra, and Il10ra.
(C) Mean fluorescence intensities of IL4RA, IL6R,
and IL10RA protein levels were assessed by flow
cytometry in macrophages and T cells isolated
from RT2 tumors.
(D) Expression of Ccl8, Ccl12, and F13a1 was
analyzed by qRT-PCR.
Data are presented as mean ± SEM of expression;
levels are relative to the mixed live-cell population
from n = 3 independent biological replicates. The
relative expression level of the live-cell population
is set to 1 and denoted by the dotted line. See also
Figure S1.that several TH2-associated cytokines coordinately activate
STAT6 (the downstream effector of IL-4 and IL-13) and STAT3
(the downstream effector of IL-6 and IL-10) to regulate TH2 cell
differentiation (Stritesky et al., 2011), suggesting a crosstalk
mechanism responsive to multiple cytokine inputs. However, it
is currently unknown whether similar machinery also operates
in macrophages to modulate their activation and functions.
To address this question, we have used genetic approaches to
demonstrate that both STAT3 and STAT6 signaling critically
contribute to tumor development and cancer cell invasion
in vitro and in vivo. We determined that STAT3/STAT6-activating
cytokines cooperate to regulate cathepsin expression and, more
potently, secretion in bone marrow (BM)-derived macrophages
(BMDMs). Whole-genome expression analyses revealed that
combined cytokine treatment of BMDMs led to pronounced
transcriptional reprogramming highlighted by the upregulation
of secretion-associated genes. Furthermore, we found that the
synergistic induction of the secretion of pro-cathepsins is pre-
dominately regulated by activation of the inositol-requiring
enzyme 1a (IRE1a) axis of the unfolded protein response (UPR)
pathway.Cell ReportsRESULTS
Genetic Deletion of Components of
the STAT3 and STAT6 Cytokine
Signaling Pathways Impairs
Tumorigenesis
TAMs reside in complex microenviron-
ments that are typically TH2 skewed (Bis-
was and Mantovani, 2010; Shiao et al.,
2011). Previously, we showed that the
TH2 cytokine IL-4, which is progressively
upregulated during pancreatic neuroen-
docrine tumor (PanNET) development in
the RIP1-Tag2 (RT2) mouse model, is an
important inducer of high global cysteinecathepsin activity in TAMs, which peaks in the most invasive of
RT2 tumors (Gocheva et al., 2010b). However, in this earlier
study, we did not address whether the overall increase in pan-
cathepsin activity was the result of transcriptional, translational,
or localization changes in specific cysteine cathepsin family
members, of which there are 11 in humans (Turk et al., 2012).
Moreover, given that Il4 deletion only reduced the proportion of
cathepsin-activity-high TAMs by approximately 40% (Gocheva
et al., 2010b), additional cytokines in the TME are likely to regu-
late this important phenotype of TAMs.
To directly interrogate TH2-associated cytokine signaling pro-
grams in vivo, we first quantified the expression levels of the
signaling components in individual cell populations within the
PanNET TME. We used fluorescence-activated cell sorting
(FACS) to isolate TAMs, T cells, and cancer cells, based on their
distinct patterns of surface marker expression. Separation of
pure cell populations was confirmed by exclusive expression
of Cd68 in macrophages, Cd3e in T cells, and SV40-Tag in can-
cer cells (Figure S1A). qRT-PCR analysis showed that Il4, Il10,
and Il13 were mainly expressed in T cells or TAMs, while Il6
was uniformly expressed across all cell populations (Figure 1A).16, 2914–2927, September 13, 2016 2915
Figure 2. Genetic Deletion of STAT3 and
STAT6 Signaling Pathways Blunts RT2 Tu-
mor Development and Invasion
(A and B) RT2 mice developed multiple tumors by
the end-stage 13.5-week time point, and cumu-
lative tumor volume was determined for each ge-
notype. Mice with constitutive deletion of (A) Il4ra
(n = 24 for Il4ra+/; n = 40 for Il4ra/) or (B) Stat6
(n = 48 for Stat6+/; n = 39 for Stat6/) were
compared with the corresponding littermate con-
trols (n = 31 for Il4ra cohorts; n = 57 for Stat6
cohorts).
(C) The cumulative tumor volume in each RT2
mouse with conditional deletion of Stat3 by
LysM:Cre (n = 39 for Stat3+/D; n = 21 for Stat3D/D)
was determined at 13.5 weeks of age and
compared with the corresponding littermate con-
trols (n = 34).
(D) Tumor volume plot shows the double-knockout
RT2 mice with constitutive deletion of Stat6 and
LysM:Cre-mediated deletion of Stat3. Tumor vol-
umes (n = 47 for Stat3+/D Stat6/; n = 17 for
Stat3D/D Stat6/) were compared with littermate
controls (n = 54). Tukey box-and-whisker plots are
shown in (A–D) with values outside the whiskers.
All data points were included in statistical ana-
lyses. All comparisons of tumor volumes were
analyzed using Kruskal-Wallis tests with Dunn’s
multiple comparisons.
(E) H&E staining was performed, and tumors fromStat3D/D (n = 11),Stat6/ (n = 10),Stat6/-Stat3D/D (n = 9), andWT littermates (n = 13) were classified into three
categories: encapsulated (green), microinvasive (IC1, blue), and invasive (IC2, red). The relative proportions of the three categories in each genotype are shown in
each column. The distributions of tumor invasion were compared using a cumulative logit model with generalized estimating equations to correct for correlations
within individual mice. *p < 0.05; **p < 0.01; ***p < 0.001; n.s., non-significant.Specifically, T cells expressed the highest levels of Il4 and Il13,
whereas Il10 expression was most prominent in macrophages
(Figure 1A). TAMs expressed the corresponding cytokine recep-
tors at both the mRNA and protein levels (Figures 1B and 1C), as
well as the downstream transcriptional mediators Stat3 (for IL-6
and IL-10) and Stat6 (for IL-4 and IL-13) (Figure S1B). We found
that TAMs expressed high levels of genes associated with an
IL-4-driven alternative-activation phenotype, including Ccl8
(Hiwatashi et al., 2011), Ccl12, and F13a1 (Ostuni et al., 2013),
indicating the capacity of TAMs to receive the TH2 cytokine in-
puts (Figure 1D).
We next examined the role of TH2-associated cytokine
signaling in tumor development by genetically deleting multiple
components of the IL-4 signaling axis in the RT2 model. End-
stage analysis at 13.5 weeks revealed that mice with constitutive
deletion of the Il4ra receptor led to a significant decrease in
tumor burden compared to wild-type (WT) RT2 animals (Fig-
ure 2A). Genetic deletion of Stat6, the critical downstream medi-
ator of IL-4Ra signaling, also resulted in a significant decrease in
cumulative tumor volume (Figure 2B). Because heterozygous
Stat6 deletion resulted in a similar reduction in tumor burden,
compared to Stat6 homozygous knockouts (Figure 2B), we
sought to determine whether Stat6+/ BMDMs still respond to
IL-4 stimulation (Figure S1C). Our data suggest that, while
Stat6+/ BMDMs retained some responsiveness to IL-4, the
magnitude of IL-4-mediated activation was significantly attenu-
ated, as indicated by the diminished induction of Arg1, Ccl22,2916 Cell Reports 16, 2914–2927, September 13, 2016Ccl8, and Ccl12 (Figure S1C). Therefore, the reduction of tumor
volume observed in Stat6+/ RT2 mice may be the result of
partial Stat6 loss in both TAMs and tumor cells.
To define the contribution of BM-derived cells to these pheno-
types, we performed BM transplantation (BMT) experiments.
We have previously shown that the vast majority (88%) of BM-
derived cells in RT2 tumors differentiate into TAMs (Gocheva
et al., 2010b); thus, BMT provides a strategy to experimentally
manipulate the expression of TAM-supplied factors such as
STAT6 in vivo. We transferred WT or Stat6/ donor BM into
lethally irradiated WT RT2 recipients at 4 weeks of age and sub-
sequently assessed end-stage tumor volume at 13.5 weeks.
Mice transplanted with Stat6/ BM showed a markedly lower
tumor burden compared to WT BM counterparts (Figure S1D).
Together, these findings demonstrate that the IL-4/ STAT6
signaling pathway critically contributes to tumor development.
The presence of intratumoral STAT3-activating cytokines (IL-6
and IL-10) in the TME prompted us to also delineate the role of
STAT3 in PanNET development. Stat3-deficient animals are em-
bryonic lethal (Takeda et al., 1997); therefore, we conditionally
deleted Stat3 in myeloid cells of RT2 mice using the LysM:Cre
line (here after termed Stat3D/D) (Takeda et al., 1999). Mice with
a heterozygous or homozygous Stat3 deletion showed a signifi-
cantly lower tumor burden compared to WT RT2 (Figure 2C). To
next determine whether Stat6 and Stat3 act in an additive or
epistatic manner, we generated Stat6/ RT2 mice with either
a heterozygous or a homozygous Stat3 deletion in myeloid cells
and analyzed end-stage tumor burden. Compared to Stat6/
mice, animals with an additional Stat3 deletion had significantly
lower tumor volume (Figure 2D). Collectively, these genetic ex-
periments show that STAT6 and STAT3 synergistically regulate
PanNET progression in vivo.
STAT3 and STAT6 Signaling Enhance Tumor Invasion
Previously, we have shown that IL-4 increases pan-cathepsin
activity in TAMs and that TAMs, in turn, promote cancer cell in-
vasion (Gocheva et al., 2010b). Therefore, we examined the ef-
fect of genetically ablating STAT3/STAT6 signaling components
on tumor invasiveness in vivo. Based on histological features,
RT2 tumors are classified into encapsulated tumors, microinva-
sive carcinomas (IC1), and frankly invasive carcinomas (IC2), as
previously described (Lopez and Hanahan, 2002; Gocheva et al.,
2010b).WTRT2 tumors comprise all three grades, with IC1 being
the predominant type. To determine the impact of STAT6
and STAT3 on tumor invasion, we compared Stat6/ tumors,
Stat3D/D tumors, and Stat6/ Stat3D/D tumors with their WT
counterparts. Stat6 deletion significantly impaired tumor inva-
sion compared to WT. While deletion of Stat3 also trended to-
ward reduced tumor invasion, this was not statistically significant
compared to WT tumors (Figure 2E). Similarly, the combined
ablation of both Stat6 and Stat3 did not further decrease tumor
invasion compared to Stat6 deletion alone, though there was
a trend toward less IC2-invasive tumors. In sum, these results
suggest that perturbation of the STAT6 signaling pathway is
sufficient to limit the invasive capacity of tumors.
STAT3/STAT6-Activating Cytokines Cooperate to
Regulate Cathepsin Transcription and Secretion by
Macrophages
Given that STAT3 and STAT6 cooperate during TH2 cell develop-
ment (Stritesky et al., 2011), and given their synergistic functions
in promoting RT2 tumor growth and invasion (Figure 2), we
hypothesized that concurrent activation of STAT6 and STAT3
could potently enhance the pro-tumorigenic functions of macro-
phages. We specifically focused on macrophage-derived ca-
thepsins, because abundant evidence has established their
importance in PanNET progression and invasion (Joyce et al.,
2004; Gocheva et al., 2006, 2010a, 2010b; Akkari et al., 2014,
2016). We first stimulated BMDMs with either IL-4 alone or a
‘‘cytokine cocktail’’ (comprising IL-4, IL-6, IL-10, and IL-13) for
6 consecutive days. We specifically analyzed expression of the
6 of 11 cathepsin family members (CtsB, C, H, L, S, and Z) that
we had previously shown to be upregulated during multistage
RT2 tumorigenesis (Joyce et al., 2004). Expression analysis
demonstrated modest additional upregulation of CtsB, CtsC,
CtsS, and CtsZ mRNA after combined cytokine stimulation
compared to IL-4 stimulation alone (Figure 3A). The mRNA level
of CtsL, however, was dramatically elevated by the cytokine
cocktail compared to IL-4 (Figure 3A). CtsH was the only family
member that did not show further enhanced expression by
combined cytokines (Figure 3A). These findings highlight the dif-
ferential transcriptional regulation of cathepsin family members
following TH2-associated cytokine treatment.
Next, we analyzed the levels of secreted cathepsins under
individual and combinatorial cytokine conditions using macro-phage-conditioned media (CM) labeled with DCG-04 (Green-
baum et al., 2000), a pan-cathepsin probe that has been widely
used to assay cathepsin abundance and activity (e.g., Joyce
et al., 2004; Rooney et al., 2005; Vasiljeva et al., 2006; Chandra-
mohanadas et al., 2009). While IL-4 and the other TH2-
associated cytokines increased pan-cathepsin secretion, the
‘‘cocktail’’ treatment resulted in the most robust response (Fig-
ure 3B), with all treatments leading to some increase in overall
protein secretion compared to controls (Figure S2A). Interest-
ingly, a substantial proportion of cathepsins were secreted as
pro-forms, as indicated by the alterations of their molecular
weights following incubation in cathepsin activation buffer (Fig-
ure 3B). Western blots for individual cathepsins confirmed that
combined cytokine treatment robustly upregulated the secretion
of CtsB, CtsL, CtsS, and CtsZ (Figure S2B). Compared with sin-
gle cytokines, combined cytokines also triggered upregulation
of intracellular CtsL protein but not the other cathepsins (Fig-
ure S2C), which corresponds to the pronounced transcriptional
induction of CtsL (Figure 3A). By contrast, discordance between
transcriptional and secretory regulation is highlighted by the
lack of alteration in CtsC secretion following combined cytokine
treatment (Figure S2B), despite a modest increase at the mRNA
level (Figure 3A). Cathepsin secretion was more potent with IL-4,
as IL-13 did not further promote cathepsin secretion when
combined with IL-6 or IL-10 (Figures S3A–S3D). These results
demonstrate that cathepsin abundance and localization are
differentially regulated by TH2-associated cytokines, with secre-
tion being the most prominent effect.
To gain further insight into these regulatory complexities, we
focused on the downstreammediators of TH2 cytokine signaling,
STAT6 and STAT3. We combined IL-4 with either IL-6 or IL-10
to non-redundantly stimulate WT, Stat6/, or Stat3D/D BMDMs.
Both cytokine combinations resulted in a synergistic upregula-
tion of cathepsin secretion by WT BMDMs, which was abolished
by Stat6 or Stat3 inactivation (Figure 3C). Taken together, our
data suggest that both STAT6 and STAT3 are required for
the TH2-associated cytokine-induced synergistic secretion of
cathepsins by macrophages.
Combined Cytokine Stimulation Reshapes the
Transcriptional Landscape of Macrophages toward a
Secretory Phenotype
We determined that, although STAT6 and STAT3 were capable
of mediating cathepsin transcription, their direct transcriptional
regulation was modest and, therefore, not sufficient to explain
the greater magnitude of the enhanced secretory phenotype
for several cathepsin family members. We reasoned that addi-
tional STAT6 and STAT3 targets might mediate the synergistic
cathepsin secretion from stimulated BMDMs. Therefore, we per-
formed whole-genome expression profiling to gain systematic
insights into cytokine-mediated transcriptional changes in mac-
rophages. Principal-component analysis (PCA) revealed that
IL-4 induced a distinct repertoire of transcriptional changes in
BMDMs, compared with IL-6 or IL-10, and combined cytokines
modified the transcriptional landscape differently from single cy-
tokines (Figure 4A). When analyzing the interactions between
IL-4 and IL-6, we defined six patterns of gene expression: (I)
genes upregulated by IL-4 but not by IL-6 or the combinationCell Reports 16, 2914–2927, September 13, 2016 2917
Figure 3. TH2-Associated Cytokines Synergize to Enhance Cathepsin Expression and Pro-formCathepsin Secretion in a STAT3- and STAT6-
Dependent Manner
(A) Wild-type bone marrow-derived macrophages (BMDMs) were stimulated with either IL-4 (10 ng/ml) alone or a ‘‘cytokine cocktail’’ (including IL-4, IL-6, IL-10,
and IL-13; 10 ng/ml each) for up to 6 consecutive days. The transcripts ofCtsB,CtsC,CtsH,CtsL,CtsS, andCtsZwere quantified by qRT-PCR. Data are shown as
themean ± SEM of n = 3 independent experiments. One-way ANOVA, followed by Fisher’s least significant difference (LSD), test was used to assess significance
between IL-4 and the ‘‘cytokine cocktail’’ treatment group.
(B) BMDMs were stimulated with indicated cytokines for 48 hr, followed by 24-hr conditioning in serum-free media. Equal volumes of conditioned media (CM)
were then labeled with the cathepsin probe DCG-04 and analyzed by immunoblotting (left). In parallel, CMwas activated in vitro, using cathepsin activation buffer,
and subsequently labeled with DCG-04. Immunoblotting was performed to assess cathepsin levels (right). SC, single chain; HC, heavy chain.
(C) BMDMs derived fromWT, Stat6/, and Stat3D/Dmice were stimulated with individual or combinatorial cytokines (10 ng/ml each) for 48 hr and then cultured in
serum-free media for 24 hr to generate CM. CM were then labeled with DCG-04, followed by immunoblotting. Results are representative of n = 3 independent
biological replicates. ‘‘Pro-’’ indicates pro-form. Protein sizes (in kilodaltons) are indicated on the left of each blot. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
See also Figures S2 and S3.
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Figure 4. Combined Cytokine Stimulation Elicits Non-additive Transcriptional Programs
BMDMswere either untreated or treated for 24 hr with IL-4, IL-6, IL-10, IL-4 + IL-6 together, or IL-4 + IL-10. RNAwas isolated, and gene expression changes were
assessed by microarrays.
(A) Principal-component analysis (PCA) of gene expression data shows clear separation of the combined-cytokine from the single-cytokine treatment group.
Each dot represents a biological replicate for the indicated treatment group. The first principal component (PC) is shown on the x axis, and the second PC is
shown on the y axis, accounting for 52% and 19% of the total variance, respectively.
(B) Venn diagram of upregulated genes in IL-4 versus unstimulated, IL-6 versus unstimulated, and combined IL-4 + IL-6 versus unstimulated conditions. Six
patterns of expression for upregulated genes were identified, and the numbers of genes are indicated for each pattern (fold change ± 2, FDR 0.05%): (I) genes
upregulated by IL-4 but not by IL-6 or the combination of IL-4 + IL-6; (II) genes upregulated by IL-6 but not by IL-4 or the combination of IL-4 + IL-6; (III) genes
upregulated by IL-4 and by IL-4 + IL-6 together but not by IL-6 alone; (IV) genes upregulated by IL-6 and by IL-4 + IL-6 but not by IL-4 alone; (V) genes upregulated
by IL-4, IL-6, and the combination of IL-4 + IL-6; and (VI) genes responsive only to the combination of IL-4 + IL-6.
(C) Heatmap of genes corresponding to the Venn diagram in (B).
(D) Log2 gene expression values (microarray) for Irf4, Retnla, and Cd163.
See also Figure S4 and Table S1.
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of IL-4 + IL-6; (II) genes upregulated by IL-6 but not by IL-4 or the
combination of IL-4 + IL-6; (III) genes upregulated by IL-4 and by
IL-4 + IL-6 together but not by IL-6 alone; (IV) genes upregulated
by IL-6 and by IL-4 + IL-6 but not by IL-4 alone; (V) genes upre-
gulated by IL-4, IL-6, and the combination of IL-4 + IL-6; and (VI)
genes responsive only to the combination of IL-4 + IL-6 (Fig-
ure 4B; complete gene expression results can be found in
Table S1). We found 133 genes upregulated by IL-4 treatment,
including well-known responsive genes such as Arg1, Ccl17,
Ccl22, and Irf4 (El Chartouni et al., 2010; Wang and Joyce,
2010) (Figures 4B and 4C). In addition we found that both IL-6
and IL-4 + IL-6 stimulation induce ll4ra (Figures 4B, 4C, and
S4B), a finding previously proposed to support the role of IL-6
in alternative macrophage activation (Mauer et al., 2014).
Moreover, 187 genes (pattern IV, including Cd163, Cd209a/
DC-SIGN, and Cd274/ PD-L1) were upregulated by IL-4 + IL-6
in combination but showed no response to either cytokine alone
(Figures 4B and 4C). These data highlight that cytokine interac-
tions result in complex changes in the transcriptome in a non-ad-
ditive manner.
In accordance with PCA, we found that there was consider-
able transcriptional similarity between IL-6-stimulated and
IL-10-stimulated BMDMs, with onlyRsad2 and Ifit3 being specif-
ically upregulated in IL-6-treated macrophages (Figures 4A and
S4A). Despite such a substantial overlap in transcriptional regu-
lation, concurrent IL-4 stimulation dramatically amplified the
differences between IL-6 and IL-10, withmanymore genes being
differentially regulated in the combination conditions (Figures 4A,
S4A, and S4B). Specifically we found 33 genes upregulated
by combined IL-4 + IL-6, compared to IL-4 + IL-10, including
Il4ra, Socs3, and Cd209a (Figures 4C, S4A, and S4B). Mean-
while, 13 genes were upregulated in response to combined
IL-4 + IL-10 compared to IL-4 + IL-6, including Ccl17, Ccl22,
and Irf4 (Figures 4C and S4B). These findings demonstrate the
non-redundancy of the two STAT3-activating cytokines IL-6
and IL-10 when combined with IL-4 stimulation.
To comprehensively assess these complex cytokine interac-
tions, we used an interaction-based linear model to statistically
quantify the extent to which target genes were regulated by sin-
gle and combination cytokine treatments (Ritchie et al., 2015).
This approach allowed us to more accurately distinguish IL-4-
responsive genes (pattern III) from exclusively IL-4 + IL-6-
responsive genes (pattern VI) for broader gene ontology (GO)
analyses. In the most extreme cases, ‘‘induced’’ genes (n = 82)
showed minimal response to single cytokines but striking in-
creases in gene expression upon combined cytokine stimulation
(Figure 5A). Conversely, ‘‘repressed’’ genes (n = 61) showed the
opposite trend, where either of the combined cytokine treat-
ments led to a decrease in expression (Figure 5A). In addition,
we observed globally that the magnitude of synergy was most
pronounced in the combined IL-4 + IL-6 condition, whereas
IL-4 + IL-10 treatment led to a modest response (Figure S4C),
confirming the trends observed for individual genes (Figure 4D).
We next sought to summarize these global changes in gene
expression using GO analysis. We focused on the combined
IL-4 + IL-6 interaction term to assign a ‘‘synergy score’’ to
each gene and assessed GO enrichment using iPAGE (Goodarzi
et al., 2009). Interestingly, GO analysis uncovered an enrichment2920 Cell Reports 16, 2914–2927, September 13, 2016of Golgi-vesicle trafficking for the genes with the highest synergy
score (Figure 5B, far right column), which contains GO terms
related to secretion, vesicle transport, and exocytosis (Fig-
ure S4D). These findings highlight the phenotypic switch of
macrophages to a secretory state upon combined cytokine
stimulation.
Combined Cytokine Treatment Activates the UPR
Given these findings, we next sought to understand the mecha-
nisms regulating protease secretion following combined cyto-
kine treatment. Having already identified a role for STAT6 and
STAT3 in mediating cathepsin secretion (Figure 3C), we utilized
MARA (Suzuki et al., 2009) to gain additional mechanistic insight
into putative downstream pathways regulating this process. As
expected, transcription factor (TF) motifs representing STAT6
and STAT3 demonstrated increased activity under both individ-
ual and combined cytokine conditions compared to the unstimu-
lated condition (Figure S4E).We next focused our attention on TF
motifs that demonstrated synergistic induction in response to
combined cytokine treatment in order to identify pathways regu-
lating secretion and vesicle trafficking-related processes. We
identified eight TF motifs that were induced under the combined
cytokine condition: NFE2, ATF6, Rfx-family members, HOXA5/
B5, NR1H4, ATF2, ARNT, and XBP1 (Figure 5C). Only XBP1
and ATF6 targets were enriched for Golgi vesicle-related GO
terms (Figures 5C and 5D). Interestingly, these factors have
been shown to be the major mediators of the UPR; XBP1, in
particular, has been implicated in antibody secretion from
plasma cells (Reimold et al., 2001; Osorio et al., 2014). Collec-
tively, these analyses suggest that combined cytokine stimula-
tion activates UPR-associated TFs in macrophages, potentially
resulting in a phenotypic switch to a secretory state.
There are three arms of the classical UPR,mediated via IRE1a/
XBP1, PERK, and ATF6, respectively, which are critical for
regulating protein aggregates, thereby preventing endoplasmic
reticulum (ER) stress (Bettigole and Glimcher, 2015). We first
analyzed Xbp1 splicing, which serves as a readout of upstream
IRE1a activation. Consistent with the TF MARA analyses,
spliced-Xbp1 (sXbp1) was significantly upregulated under the
combined cytokine conditions (Figures 6A and S5A). A time-
course analysis of Xbp1 splicing revealed induction as early as
2 hr post-stimulation, which peaked at 24 hr and remained
elevated after 48 hr (Figure 6B). By contrast, Stat6/ and
Stat3D/D BMDMs showed either severely attenuated or no
sXbp1 induction upon combined cytokine stimulation (Figures
6C, 6D, and S5A). Similar kinetics of IRE1a phosphorylation
and its Stat3/ Stat6 dependence were identified, indicating acti-
vation of this pathway (Figure S5B).
Next, we assessed activation of the PERK pathway, another
arm of the UPR, which was modestly activated by combined cy-
tokines (Figure 6E). To determine whether there was a functional
contribution of the PERK pathway to cathepsin secretion,
BMDMs were pre-incubated with a pharmacological inhibitor
of PERK, GSK2606414, followed by cytokine stimulation. How-
ever, PERK inhibition did not significantly alter the synergistic
cathepsin secretion induced by combined cytokines (Figure 6F).
Finally, we examined the third component of the classical UPR,
ATF6. Following IL-4 + IL-6 treatment, we did not detect robust
Figure 5. TH2-Associated Cytokine Treatment Leads to Synergistic Gene Expression Changes and Engagement of the UPR
(A) Synergistic and antagonistic genes were identified using an interaction-based linear model as described in the Experimental Procedures. Log2 coefficients for
induced genes (n = 82) are plotted in red, and those for repressed genes (n = 61) are plotted in blue.
(B) The coefficient for the combined IL-4 + IL-6 interaction term in the linear model (A) was used to assign a ‘‘synergy score’’ to each gene. Genes were ranked
based on ‘‘synergy score,’’ and gene ontology (GO) analysis was completed using iPAGE. Over-represented and under-represented terms were scored using
Fisher exact tests. Representations of the ensuing p values were plotted so that the overrepresented scores are shown in red and underrepresented scores are
shown in blue.
(C) Transcription factor (TF) motif activity scores were generated usingMARA. Synergistic activation of TF activity was identified using an interaction-based linear
model, and the combined IL-4 + IL-6 interaction coefficient is shown here. GO enrichment for predicted TF targets was assessed in MARA. TF families enriched
for ‘‘Golgi-vesicle-trafficking’’-related GO terms are labeled in red (XBP1 and ATF6). A hypergeometric test was used for the statistical analysis of GO enrichment
terms. *p < 0.05; **p < 0.01.
(D) Normalized model coefficients from (C) for XBP1 and ATF6, where each dot represents a biological replicate for the indicated treatment group.
See also Figure S4.alterations in ATF cleavage or its nuclear localization (Figure 6E).
When compared with UPR triggered by bona fide activators,
including tunicamycin and thapsigargin, combined cytokine-mediated UPR shows modest induction of targets (Figures
S5A and S6A). In addition, IL-4 is a more potent inducer of
UPR than IL-13 when combined with IL-6 or IL-10 (Figure S6B).Cell Reports 16, 2914–2927, September 13, 2016 2921
Together, these findings suggest that TH2-associated cytokines
trigger an attenuated, non-canonical UPR in macrophages,
which potentially leads to the secretory phenotype.
Inhibition of IRE1a Blocks Cathepsin Secretion and
Macrophage-Driven Cancer Cell Invasion
Having excluded a role for PERK or ATF6 in controlling the secre-
tory phenotype, we therefore sought to determine whether
IRE1a was the key regulator. Transient small interfering RNA
(siRNA)-mediated knockdown of IRE1a resulted in significant
attenuation in UPR induction by combined cytokines (Figures
S7A and S7B). We also used a small-molecule inhibitor of the
RNase domain of IRE1a, STF-083010 (Papandreou et al.,
2011), to assess the role of IRE1a in UPR induction in macro-
phages. We found that STF-083010 blocked cytokine-induced
Xbp1 splicing (Figure S7C) and sXBP1 protein abundance (Fig-
ure S7D), indicating functional inhibition of IRE1a. Similarly, the
induction of UPR genes (Bip and Pdi) was also dependent
upon IRE1a activity (Figure S7C).
We then investigated whether perturbation of IRE1a would
blunt TH2 cytokine-mediated cathepsin secretion. IRE1a knock-
down completely abolished cathepsin secretion from BMDMs
treated with combined cytokines (Figure 7A). This finding
was further corroborated by using three independent IRE1a
pharmacological inhibitors, STF-083010, 4m8C, and KIRA6 (Fig-
ures 7B, S7E, and S7F). Interestingly, this phenomenon appears
to extend beyond cathepsins, as secretion of the lysosomal
enzyme legumain (LGMN) also depended on IRE1a activity (Fig-
ures 7A, 7B, S7E, and S7F). By contrast, the secretion of
MMP9 and MMP13, two representative matrix metalloproteases
(MMPs) produced in abundance by macrophages, was not
synergistically regulated by combined cytokines, and IRE1a
inhibition did not block MMP secretion (Figures 7A and 7B).
Together, these findings indicate that IRE1a-dependent syner-
gistic secretion of proteins from macrophages is specific to a
subset of lysosomal proteases.
Our invivodatasuggest thatTAMscanenhance tumor invasion.
To investigate how cytokine signaling in TAMs promotes this pro-
cess, we utilized a transwell invasion assay in which bTC374 can-
cer cells (a cell line derived from aWT RT2 tumor) were plated on
reconstituted ECMpre-processedwith CM from cytokine-primed
BMDMs. We found that CM from combined cytokine-treated
BMDMs resulted in the highest enhancement of cancer cell inva-
sion, whereas single-cytokine priming led to no significant alter-
ation in invasion (Figure 7C). Considering the marked effect of
TH2-associated cytokines on cathepsin secretion, we used a
pan-cathepsin inhibitor, JPM-OEt, to determine whether cathep-
sins are responsible for macrophage-mediated cancer cell inva-
sion. Indeed, the addition of JPM-OEt abolished cancer cell inva-
sion mediated by combined cytokine-treated BMDMs, indicating
the crucial role of cathepsins in driving this process (Figure 7C).
Moreover, the IRE1a inhibitor STF-083010 similarly impaired the
ability of combined cytokine-stimulated BMDMs to promote tu-
mor cell invasion (Figure 7C), which was likely caused by dimin-
ished cathepsin secretion. Taken together, our data demonstrate
that TH2-associated cytokines synergistically promote cathepsin
secretion by macrophages in an IRE1a-dependent manner,
which, in turn, facilitates cancer cell invasion.2922 Cell Reports 16, 2914–2927, September 13, 2016DISCUSSION
Macrophages are capable of performing diverse functions in
response to various signaling inputs. Previously, we showed
that, in addition to its role in driving M2-like/alternative polariza-
tion, IL-4 upregulates cathepsin activities in TAMs to facilitate tu-
mor development (Gocheva et al., 2010b). Here, using genetic
strategies, we found that deletion of TH2 cytokine signaling com-
ponents in TAMs is sufficient to impair tumor growth and invasion
in vivo, a finding that mirrored previous results where we showed
that TAM-derived CtsB and CtsS played critical roles in RT2 tu-
mor growth and invasion (Gocheva et al., 2010b). In the present
study, we demonstrate that IL-4 cooperates with other cyto-
kines—specifically, IL-6 and IL-10—tomediate the synergistic in-
duction of cathepsin transcription and secretion in BMDMs. We
found that the enhanced secretory phenotype of macrophages
is concomitant with engagement of the UPR. Strikingly, transient
knockdown and pharmacological inhibition of IRE1a led to a
complete blockade in cathepsin secretion and a subsequent
reduction in macrophage-mediated cancer cell invasion.
This study presents evidence for the first time that TH2 cyto-
kines and IRE1a regulate protease secretion frommacrophages,
an effect that was specific to the secretion of pro-form lysosomal
proteases but not MMPs. This pro-form protease secretion
suggests a potential re-routing of lysosomal proteases before
they reach the lysosome, as we found no change in lysosomal
function or acidification (data not shown). In contrast, previous
reports demonstrated that interferon gamma (IFN-g), an inducer
of M1-like macrophage activation, increases the secretion of
active-form CtsL (Beers et al., 2003). One explanation for this
difference may be that combined TH2 cytokine-treated macro-
phages upregulate CtsL and concomitantly downregulate
the manose-6-phosphate (M6P) receptors Igf2r and M6pr
(Table S1). This could lead to saturation of the M6P sorting sys-
tem, whereby excess lysosomal enzymes are secreted into the
extracellular space as pro-forms.
Moreover, it has been shown that the downstream effector of
IRE1a, XBP1, controls the secretion of a subset of pro-inflamma-
tory cytokines upon TLR2 or TLR4 ligation, which polarizes mac-
rophages to an M1-like state (Martinon et al., 2010). Combined
with our findings, these data suggest that the IRE1a/ XBP1
pathway may impact secretion across different macrophage
polarization states, albeit with distinct outputs. It is also impor-
tant to note that IRE1a/ XBP1 activation may not always
be accompanied by a pronounced ER stress. In our studies,
stimulation with combined cytokines induced classical ER
stress targets (Bip, Chop, and Pdi) and activated PERK, but
did not engage the ATF6 axis. Moreover, the magnitudes of
such induction were significantly lower than those triggered by
classical ER stress inducers, such as tunicamycin and
thapsigargin.
These findings indicate that combined cytokine stimulation
may instigate a low level of ER stress or perhaps no stress at
all. Recently, CD8a+ dendritic cells have been shown to engage
the UPR in the absence of ER stress to mediate antigen cross-
presentation (Osorio et al., 2014). Similar physiological engage-
ment of the UPR has been identified in differentiating B cells
where expansion of the ER is dependent upon ATF6 and IRE1a
Figure 6. TH2-Associated Cytokines Activate the UPR
(A) WT BMDMs were stimulated with IL-4, IL-6, IL-10, or their combinations for 24 hr. The level of spliced Xbp1 (sXbp1) mRNA was measured by qRT-PCR. Data
are presented as mean ± SEM of n = 3 independent experiments.
(B–D) BMDMs from (B) WT, (C) Stat6/, and (D) Stat3D/D mice were incubated with combined cytokines (IL-4 + IL-6) for up to 48 hr. sXbp1 and total Xbp1
(tXbp1) mRNA expression were quantified by qRT-PCR. Data are presented as mean ± SEM of n = 5 (WT) or n = 3 (Stat6/ and Stat3D/D) independent
experiments.
(E) WT BMDMs were stimulated with the indicated cytokines for 24 hr, and whole-cell lysate (top two panels) or nuclear fraction (bottom two panels) was isolated
for immunoblotting of phospho-PERK (p-PERK), total PERK, ATF6 (cleaved form), and Lamin A/C (left). Relative levels of phospho-PERK were quantified using
total PERK as a normalization factor; data are presented as mean ± SEM of n = 3 independent experiments (right).
(legend continued on next page)
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Figure 7. IRE1a Inhibition Blocks Cathepsin
Secretion and Macrophage-Driven Cancer
Cell Invasion
(A) BMDMs were incubated with pooled siRNA
against Ern1, the gene encoding the IRE1a pro-
tein, or scrambled control siRNA and the indicated
cytokines (10 ng/ml each) for 48 hr. Cells were
then cultured under serum-free condition for 24 hr
to generate conditioned media (CM). DCG-04-
labeled CM was analyzed by immunoblotting for
cathepsin abundance (top panel). Immunoblotting
for legumain (LGMN), MMP9, and MMP13 pro-
teins was also performed using unlabeled CM
(lower panels).
(B) BMDMs were incubated with individual or
combinatorial cytokines, in the presence or
absence of the IRE1a inhibitor STF-083010
(100 mM) for 48 hr. As in (A), CM was assayed
for secretion of cathepsins, LGMN, MMP9, and
MMP13. Protein sizes (in kilodaltons) are indicated
on the left of each blot.
(C) CM were prepared from BMDMs treated
with the indicated cytokines in the presence or
absence of STF-083010. CM were activated in
cathepsin activation buffer and then applied onto
Matrigel-coated FluoroBlok inserts in the pres-
ence or absence of the pan-cathepsin inhibitor
JPM-OEt (100 mM). After 24 hr of matrix process-
ing, bTC374 cancer cells were plated onto the
inserts, and cell invasion proceeded for 48 hr.
The level of invasion in each condition was quan-
tified by counting the number of DAPI+ cancer
cells. Data from n = 9 independent experiments
are shown as Tukey box-and-whisker plots, with
values outside the whiskers. All data points were
included in statistical analyses. Ordinary one-way
ANOVA with Holm-Sidak’s multiple comparisons
test was used for statistical analysis. *p < 0.05;
***p < 0.001.
See also Figure S7.and, importantly, precedes the production of immunoglobulin
(Iwakoshi et al., 2003; van Anken et al., 2003). In addition, thy-
roid-stimulating hormone-stimulated thyrocytes activate the
UPR preemptively to maintain thyroglobulin secretion (Christis
et al., 2010). In light of these reports, our data suggest that mac-
rophages stimulated with IL-4 and IL-6/ IL-10 may engage the
IRE1a/XBP1 pathway tomediate the secretory load of lysosomal
proteases.(F) BMDMs from WT mice were treated with the indicated cytokines and with a PERK inhibitor GSK
CM were then collected and immunoblotted for CtsB, CtsC, CtsH, CtsL, CtsS, and CtsZ. Protein sizes (in
Ordinary one-way ANOVA with Holm-Sidak’s multiple comparisons test was used for statistical analysi
Figures S5 and S6.
2924 Cell Reports 16, 2914–2927, September 13, 2016Our results also emphasize cathepsin
proteaseproductionasa functional aspect
of the tumor-promoting TAM phenotype.
Wepreviously found thatcathepsinactivity
increases during the course of disease
progression inPanNETsandbreastcancer
and that TAM-supplied cathepsins sub-stantially contribute to tumor growth, invasion, and angiogenesis
in a PanNET mouse model, with the highest level of cathepsin
activity present in invasive IC2 tumors (Gocheva et al., 2010b).
In concordance with previous reports showing IL-6-mediated
transcriptional control of CtsB (Mohamed et al., 2010), our data
herein indicate that cathepsin production in TAMs is, at least
partially, regulated by a group of TH2-associated cytokines, which
are abundant in the PanNET TME. These results also represent an2606414 (500 nM) or vehicle (DMSO) for 48 hr.
kilodaltons) are indicated on the left of each blot.
s. *p < 0.05; **p < 0.01; ***p < 0.001. See also
interesting comparison with the report that lipopolysaccharide
(LPS)-stimulated macrophages robustly upregulate a variety of
M1-associated cytokines, including CXCL1 and IL-1b, but not
cathepsins (Meissner et al., 2013). Therefore, we propose that a
high level of pro-form cathepsin secretion is a characteristic of
M2-like macrophages, such as TAMs, and that extracellular
cathepsin-mediated proteolysis coordinates with other TAM-me-
diatedprocesses, suchas immunosuppression andangiogenesis,
to promote tumor development.
In conclusion, we have demonstrated that complementary
TH2-associated cytokines lead to a distinct macrophage activa-
tion state characterized by a robust secretory capacity. These
cytokines engage a non-canonical IRE1a axis to promote
cathepsin secretion, thus promoting tumor progression and
invasion. Given that several cathepsin inhibitors have minimal
toxicities (Palermo and Joyce, 2008) and deliver therapeutic effi-
cacy in preclinical PanNET models (Joyce et al., 2004; Elie et al.,
2010), our findings further emphasize the potential of cathepsin
inhibition as a therapeutic strategy in pancreatic neuroendocrine
tumors and other cancers.
EXPERIMENTAL PROCEDURES
Mice, Cell Lines, and Pharmacological Inhibitors
The generation of RT2 (Hanahan, 1985), Il4ra/ (Noben-Trauth et al., 1997),
Stat6/ (Kaplan et al., 1996), LysM:Cre (Clausen et al., 1999), andStat3Flox/Flox
(Takeda et al., 1998) mice have been reported previously. The Il4ra/ and
Stat6/ mice were purchased from Jackson Laboratories. LysM:Cre and
Stat3Flox/Flox mice were obtained from Dr. Alexander Rudensky. The Il4ra/
mice, which were originally in the BALB/c background, were backcrossed
into the C57BL/6 background for ten generations. All mouse strains were
maintained in the C57BL/6 background. The animal studies were approved
by the Institutional Animal Care and Use Committee at Memorial Sloan Ketter-
ing Cancer Center (MSKCC). The bTC374 cancer cell line was derived from a
WT RT2 tumor in the J.A.J. lab. The following inhibitors were commercially
available: STF-083010 (EMD Millipore), GSK2606414 (Tocris), KIRA6 (Calbio-
chem), and 4m8C (Selleckchem). The pan-cathepsin inhibitor JPM-OEt was
synthesized by the Organic Synthesis core at MSKCC.
Tumor Volume Measurement and Invasion Analysis
Tumor burden was determined at 13.5 weeks of age for RT2 mice of all geno-
types. For invasion grading, stained pancreatic tissues were graded as previ-
ously described (Lopez and Hanahan, 2002; Gocheva et al., 2010b). For more
details, see the Supplemental Experimental Procedures.
Flow Cytometry and FACS
A single-cell suspension from RT2 tumors was stained with the antibodies
summarized in Table S2. A BD LSR II flow cytometer was used for data acqui-
sition, and data were analyzed using FlowJo software. For cell sorting, sam-
ples were sorted on a FACSAria II or MoFlo cell sorter. For more details, see
the Supplemental Experimental Procedures.
RNA Isolation and qRT-PCR
RNA was isolated using the TRIzol/chloroform method (Invitrogen), and first-
strand cDNA was synthesized using the High-Capacity cDNA Reverse Tran-
scription Kit (Invitrogen). For more details, see the Supplemental Experimental
Procedures.
Derivation and Culture of BMDMs
BM was harvested from WT, Stat6/, and LysM:Cre; Stat3Flox/Flox mice. BM-
derived cells were cultured for 7 days to generate mature macrophages. For
more details on cell culture and cell-based assays, see the Supplemental
Experimental Procedures.DCG-04 Labeling and Western Blotting
Biotinylated DCG-04 (Greenbaum et al., 2002) was synthesized by the Organic
Synthesis Core Facility at MSKCC. Labeling was performed at room tempera-
ture. For western blotting, samples were resolved in NuPAGE SDS-PAGE gels
(Invitrogen), transferred to polyvinylidene fluoride (PVDF) membranes, and de-
tected using chemiluminescence (Thermo Fisher Scientific). For IRE1a activa-
tion analysis, Phos-tag SDS-PAGE (Wako) was performed. For more details,
see the Supplemental Experimental Procedures.
Knockdown of IRE1a in BMDMs
BMDMs were transfected with pooled siRNA against Ern1, the gene en-
coding IRE1a (Dharmacon), or scrambled siRNA (Invitrogen), using Viromer
BLUE (Lipocalyx). For more details, see the Supplemental Experimental
Procedures.
Microarray and Computational Analysis
Sample Generation
BMDMs were generated as described earlier. On day 7, BMDMs were
treated with control media, IL-4, IL-6, IL-10, IL-4 + IL-6, or IL-4 + IL-10 for
24 hr (all cytokines were used at 10 ng/ml; CSF-1 was supplemented at
10 ng/ml). Cells were harvested and lysed in TRIzol. RNA isolation, library
preparation, and pre-processing were completed by the MSKCC Genomics
Core Facility using Affymetrix Mouse 430A 2.0 microarrays. All downstream
bioinformatic analyses were completed in R 3.0.1 using the Bioconductor
suite of packages. Differentially expressed genes were identified using the
‘‘limma’’ package (Ritchie et al., 2015), with a fold change cutoff of ±2 and
a false discovery rate (FDR) of 10%. These cutoffs were used to identify
synergistic and antagonistic genes in the interaction-based linear model
described here:
ExpressionGene =baselineGene + ½IL­4  bIL­4 Gene + ½IL­6  bIL­6 Gene + ½IL­10
 bIL­10 Gene + ½IL­4½IL­6  bIL­4+ IL­6 Gene + ½IL­4½IL­10  bIL­4+ IL­10 Gene:
Linear model coefficients plotted in Figures 5A and S4C were normalized to
baseline for each gene. GO analysis was performed with iPAGE, and motif ac-
tivity response analysis (MARA) was performed at http://ismara.unibas.ch/
fcgi/mara; additional details can be found in the Supplemental Experimental
Procedures.
Statistical Analysis and Plotting
Data are presented throughout as mean ± SEM, analyzed by the indicated
tests with a significance cutoff of p < 0.05. All statistical analyses were
completed in GraphPad Prism 6.0 and R 3.0.1. All tumor volume box-and-
whisker plots are drawn as Tukey boxplots, with upper whiskers extending
to the 75%valuemultiplied by 1.53 the inter-quartile range and lower whiskers
extending to the 25% value multiplied by 1.53 the inter-quartile range (Graph-
Pad Prism default Tukey options). All plotted data points were included in sub-
sequent statistical analyses as described in the figure legends. All code used
to analyze the data can be found at the following website: https://bitbucket.
org/bowmanr/joycelab-macrophage. For more details, see the Supplemental
Experimental Procedures.
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